General
Pfizer’s COVID vaccine success is worth an extra $14 billion to the US pharma giant
The success of its COVID vaccine, and the challenges faced by some of its rivals, look set to earn US pharmaceutical giant Pfizer at least an extra $US11 billion ($14.2 billion) in revenue this year.
Key points:
- Pfizer has raised its 2021 revenue forecasts for COVID vaccine sales by 73 per cent
- Click here to view the original article.
Continue Reading
-
Noosa News23 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News23 hours agoAustralia Post reintroduces weekend deliveries for Christmas parcel rush
-
Business22 hours agoWhy this investing expert is calling time on NAB shares
-
General18 hours agoFederal government funding extends cohealth GP services until July 2026